Sartori P C, Taylor M H, Stevens M C, Darbyshire P J, Mann J R
Department of Haematology, Birmingham Children's Hospital, England.
Med Pediatr Oncol. 1993;21(1):8-13. doi: 10.1002/mpo.2950210103.
Thirty children presenting with acute nonlymphoblastic leukaemia from June 1984 to December 1989 were treated at one UK centre using a West German protocol, AML-BFM-83. This consisted of Induction, an intensive outpatient-based Consolidation regimen with seven different drugs and cranial irradiation, and Continuation therapy with thioguanine and cytosine arabinoside for 2 years with additional Adriamycin in the first year. Twenty-five children achieved complete remission (83%). There were two early deaths from haemorrhage and infection and three from Induction failure. After a median follow-up time of 60 months, nine relapses have occurred, all in the bone marrow. Life table analysis revealed a probability for survival at 5 years of 47%, event-free survival 43%, and event-free interval 50%. Median bed occupancy for chemotherapy and toxicity was 41 days, with median hospital stays of 29 days for Induction, 11 days for Consolidation and less than 1 day for Continuation. This data suggests that long-term remissions can be achieved in just under half of children with acute nonlymphoblastic leukaemia while creating only modest demands on inpatient resources.
1984年6月至1989年12月期间，英国一家中心采用西德AML-BFM-83方案对30名急性非淋巴细胞白血病患儿进行了治疗。该方案包括诱导治疗、一种基于门诊的强化巩固方案（使用七种不同药物及颅脑照射）以及持续治疗（使用硫鸟嘌呤和阿糖胞苷治疗2年，第一年加用阿霉素）。25名患儿实现完全缓解（83%）。有2例因出血和感染早期死亡，3例因诱导治疗失败死亡。中位随访时间60个月后，发生了9次复发，均为骨髓复发。生命表分析显示，5年生存率为47%，无事件生存率为43%，无事件间期为50%。化疗及毒性反应的中位床位占用时间为41天，诱导治疗的中位住院时间为29天，巩固治疗为11天，持续治疗少于1天。该数据表明，近半数急性非淋巴细胞白血病患儿可实现长期缓解，同时对住院资源的需求适度。
